View Future GrowthAnbio Biotechnology 過去の業績過去 基準チェック /46Anbio Biotechnologyの収益は年間平均-3.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間36.2% 30.1%割合で 減少しています。 Anbio Biotechnologyの自己資本利益率は21.2%であり、純利益率は74.1%です。主要情報-3.45%収益成長率33.73%EPS成長率Biotechs 業界の成長17.04%収益成長率-30.09%株主資本利益率21.24%ネット・マージン74.06%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesNew Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Board Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alphaお知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.収支内訳Anbio Biotechnology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGM:NNNN 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 25962030 Sep 25843030 Jun 25734031 Mar 25824031 Dec 24823030 Sep 24932030 Jun 241041031 Mar 24831031 Dec 23721030 Sep 23822030 Jun 23923031 Mar 231662031 Dec 2224102031 Dec 214300質の高い収益: NNNN 非現金収入 のレベルが高いです。利益率の向上: NNNNの現在の純利益率 (74.1%)は、昨年(29%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NNNNの収益は過去 5 年間で年間3.4%減少しました。成長の加速: NNNNの過去 1 年間の収益成長率 ( 169.9% ) は、5 年間の平均 ( 年間-3.4%を上回っています。収益対業界: NNNNの過去 1 年間の収益成長率 ( 169.9% ) はBiotechs業界54.5%を上回りました。株主資本利益率高いROE: NNNNの 自己資本利益率 ( 21.2% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 06:01終値2026/06/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anbio Biotechnology 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Board Change • May 20High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.
お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.
Seeking Alpha • Oct 10Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched ValuationSummary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alpha
お知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.